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Abstract
The concept of intramembrane receptor-receptor interactions and evidence for their 
existence was introduced by Agnati and Fuxe in 1980/81 suggesting the existence 
of heteromerization of receptors. In 1982, they proposed the existence of aggregates 
of multiple receptors in the plasma membrane and coined the term receptor mosaics 
(RM). In this way, cell signaling becomes a branched process beginning at the level 
of receptor recognition at the plasma membrane where receptors can directly modify 
the ligand recognition and signaling capacity of the receptors within a RM. Receptor-
receptor interactions in RM are classified as operating either with classical cooper-
ativity, when consisting of homomers or heteromers of similar receptor subtypes 
having the same transmitter, or non-classical cooperativity, when consisting of heter-
omers. It has been shown that information processing within a RM depends not only 
on its receptor composition, but also on the topology and the order of receptor acti-
vation determined by the concentrations of the ligands and the receptor properties. 
The general function of RM has also been demonstrated to depend on allosteric regu-
lators (e.g., homocysteine) of the receptor subtypes present. RM as integrative nodes 
for receptor-receptor interactions in conjunction with membrane associated pro-
teins may form horizontal molecular networks in the plasma membrane coordinat-
ing the activity of multiple effector systems modulating the excitability and gene 
expression of the cells. The key role of electrostatic epitope-epitope interactions 
will be discussed for the formation of the RM. These interactions probably represent 
a general molecular mechanism for receptor-receptor interactions and, without a 
doubt, indicate a role for phosphorylation-dephosphorylation events in these inter-
actions. The novel therapeutic aspects given by the RMs will be discussed in the 
frame of molecular neurology and psychiatry and combined drug therapy appears 
as the future way to go.
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1. Introduction
The concept of intramembrane receptor-receptor 
interactions between different types of GPCRs and 
evidence for their existence was introduced by 
Agnati and Fuxe in 1980/81 through analysis of the 
effects of neuropeptides on the binding character-
istics of monoamine receptors in membrane prepa-
rations from discrete brain regions [1−3]. These 
results were in line with Lefkowitz, Limbird et al’s 
previous findings [4] showing negative cooperativity 
in β adrenergic receptors, which could be explained 
by the existence of homodimers leading to site-site 
interactions. In 1982 the Agnati and Fuxe teams 
proposed the existence of assemblies of multiple 
receptors of various types in the plasma membrane 
and coined the term receptor mosaic (RM) for the 
proposed assembly, as a molecular basis for the 
engram [5]. As a logical consequence for the indi-
cations of direct physical interactions between neu-
ropeptide and monoamine receptors the well-known 
terms heteromerization vs. homomerization was in-
troduced to describe this interaction between dif-
ferent types of GPCRs [5−7]. Thus, heteromerization 
was postulated to be the molecular mechanism for 
the intramembrane receptor-receptor interactions 
witnessed in biochemical pharmacology.
Thus, cell signaling became a branched process 
beginning at the level of receptor recognition in 
the plasma membrane where receptors can directly 
modify the ligand recognition, G protein coupling 
and signaling of the other receptor in a heterodimer 
or of other receptors in a high order receptor heter-
omer (RM) [8−10]. RM may be defined as: an assem-
blage of more than two receptors, which binds and 
decodes signals (transmitters, allosteric modula-
tors,…) to give out an integrated input, via direct 
allosteric receptor-receptor interactions, to one 
or more than one intra-cellular cascade. The term 
RM gives a better vision of the integrative actions 
and the role of the spatial organization (topology) 
for the structure of the molecular fingerprint, giv-
ing rise to the intramembrane receptor-receptor 
interactions. Different orders of activation of the 
participating receptors dependent inter alia on 
transmitter concentrations and receptor affinities 
together with stoichiometry will also determine the 
direct receptor-receptor interactions and thus the 
integrative and emergent properties of the RM and 
its functional outcome [8,10−22]. The RM does not 
include other proteins than receptor proteins and 
thus not indirect receptor-receptor interactions via 
e.g. adapter proteins.
The RMs can be located in special regions of the 
plasma membrane, called lipid rafts rich in sphingoli-
pids and cholesterol [23,24], but they are not nec-
essary for the formation of RMs [25]. The lipid rafts 
may be regarded as liquid ordered platforms pro-
viding a microenvironment that may modulate the 
operation of the RMs and their receptor interact-
ing proteins in signal integration and transduction 
involving also caveolins forming caveolae [26,27].
Early evidence for the view that GPCRs may func-
tion as dimers was obtained by Maggio et al [28] in 
1993 using chimeric α2-adrenergic/M3 muscarinic 
receptors containing the first five TM domains of 
one receptor and the last two TM domains of the 
other receptor and vice versa. Expression of the two 
chimeras alone did not lead to recognition of ligands 
or G protein coupling. However, coexpression of the 
two chimeras led to restoration of binding and sig-
naling to both adrenergic and muscarinic agonists. 
Thus, it seems possible that the two chimeras may 
directly interact to rearrange their TM domains into 
two novel binding pockets within a dimeric complex. 
Such a domain swapping can also explain the recon-
stitution of a binding site after coexpression of 
two deficient AT1 receptor mutants [29]. A compu-
tational approach has also been used to evaluate 
domain swapping in the formation of dimers [30]. 
It should be noted that domain swapping has only 
been observed for receptors with loss of function 
probably related to technical problems in demon-
strating the domain swapping in fully functioning 
receptors [17].
The first major technique used to investigate 
GPCR dimerization was coimmunoprecipitation of 
differentially epitope-tagged receptors. In 1996 
Hebert et al [31] demonstrated with this technique 
that β2-adrenergic receptors of class A form SDS 
resistant homodimers with the transmembrane (TM) 
VI being part of the interface. In fact, a peptide 
from this domain inhibited both dimerization and 
activation of the receptors. The same year Romano 
et al [32] demonstrated by Western blots that 
mGluR5 belonging to the class C is a homodimeric 
receptor becoming a monomer under reducing con-
ditions. Coimmunoprecipitation as outlined above 
showed that these results were caused by the ex-
istence of a receptor homodimer stabilized by a 
disulfide bond between the two very long extra-
cellular domains. This year it was also observed that 
the class A D2 receptors in the caudate upon solubili-
zation and immunoprecipitation exist as homodim-
ers and monomers [33]. D2-TM peptides converted 
the dimer into a monomer suggesting that the dimer 
was formed via intermolecular noncovalent inter-
actions between TM domains of the two D2 recep-
tors in line with the findings on the β2-adrenergic 
receptors [31].
A major breakthrough came in 1998 when the 
first heterodimer was discovered with the known 
GABAB receptor of class C GPCR shown to be an 
obligate heterodimer composed of subunits GABAB1 
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and GABAB2 [34,35]. The GABAB1 enabled agonist/
antagonist binding while the GABAB2 was responsi-
ble for the G protein coupling. Yeast two-hybrid 
screening was used to demonstrate the heterodimer 
which was formed via TM interactions and coiled-
coil interactions in the C-terminal tails leading to the 
formation of a functional GABAB receptor [4,36−38]. 
The two subunits could be coimmunoprecipitated 
from native brain tissue and colocalization was 
demonstrated at the ultrastructural level [39].
The heterodimerization between two functional 
GPCRs was first demonstrated by Jordan and Devi 
[40] in 1999 using again coimmunoprecipitation with 
differentially tagged κ and δ opioid receptors to 
demonstrate the kappa-delta heterodimer. Finally 
in 2000 it became possible in coimmunoprecipitation 
experiments to detect heteromeric receptor com-
plexes of A1 and D1 receptors and thus of GPCRs 
using different ligands, adenosine and DA [41]. This 
year it was also shown with immuno-affinity chro-
matography after agonist ligand affinity-labelling 
of the receptors that AT1 and B2 receptors formed 
heterodimers representing the first demonstration 
of heterodimers between two different types of 
vasoactive hormone receptors [42].
Coimmunoprecipitation of membrane receptors, 
however, has the drawback that it requires their 
solubilization with detergents. This is a problem, 
since highly hydrophobic proteins like GPCRs may 
form artifactual aggregates upon incomplete solu-
bilization. Therefore, the field of dimeric and mul-
timeric RMs demanded the direct demonstration 
that they also exist in the living cells. This was 
made possible with the development and use of 
biophysical methods based on light resonance en-
ergy transfer. Nevertheless the coimmunoprecipi-
tation technique when used with appropriate 
controls remains a highly useful method in estab-
lishing the existence of receptor heteromers espe-
cially in native tissue and can be further developed 
into demonstrating RMs in the plasma membrane 
by use of cell-impermeant crosslinking substances 
[43]. It has even been possible to demonstrate the 
trimeric potential of the M2 muscarinic cholinergic 
receptor by coimmunoprecipitation of receptor com-
plexes coexpressed in Sf9 cells with three different 
epitope tags [44].
In the present review the identification of RMs 
with BRET and FRET will be discussed. We will then 
focus on the current understanding of the hetero-
meric interface involving electrostatic epitope-
epitope interactions [45] and the structural plasticity 
of the GPCRs transferring conformational changes 
from one receptor to the other receptors in the RMs 
leading to changes in cooperativity in the binding 
sites. The functional properties of the RMs in terms 
of recognition with altered pharmaoclogy, G protein 
coupling and switching, and trafficking will also be 
covered with focus on the novel neuropsychophar-
macology created by the RMs.
In the end the role of allosteric modulators and 
receptor interacting proteins in the function of the 
RMs will also be dealt with and also the function of 
RMs built up of GPCRs and ion channel receptors or 
of GPCRs and RTKs representing integrative nodes 
for the volume and wiring transmission signals and 
for information and trophic signals, respectively.
2. Identification of RMs
2.1. FRET
Theodor Förster was the first to establish a para-
metric proportionality between the rate of trans-
fer and the radiative rate constant which operates 
over distances of 1 to 20 nm, forming the basis of the 
extensive application of Förster resonance energy 
transfer (FRET). This technique is applied extensively 
in biological research as a general “nanoruler” with 
a dynamic range corresponding to intramolecular 
and intermolecular distances of molecules control-
ling cellular functions. The molecular networks op-
erating under strict spatial-temporal conditions deal 
with binding, conformational transitions, covalent 
alterations and transport. FRET gives information 
on all these molecular interactions with high spe-
cificity and sensitivity.
FRET represents a photophysical phenomenon in 
which energy is transferred from the first excited 
electronic state of a fluorophor (donor) to another 
close by absorbing molecule (acceptor). There oc-
curs a concerted quenching of the fluorescence of 
the donor and activation of the acceptor fluores-
cence [46]. Thus, light resonance energy transfer 
approaches are based on the non-radioactive trans-
fer of excitation energy between electromagnetic 
dipoles of an energy donor and acceptor.
The most commonly used FRET pairs for tagging 
GPCRs are cyan fluorescent protein (CFP) as an en-
ergy donor and yellow fluorescent protein (YFP) as 
an energy acceptor and likewise for GFP2 and YFP, 
respectively. These fluorophors are covalently fused 
to distinct GPCRs and FRET occurs when the distance 
between the fluorophors is less than 10 nm corre-
sponding to the masses of heterodimers/heterom-
ers. Linear unmixing between the GFP2 and YFP 
emission spectra must be made since they substan-
tially overlap [25,47]. The FRET is dependent on 
the orientation of the two fluorophors and the dis-
tance between them [43,48]. In fact, the efficiency 
of FRET is inversely related to the 6th power of 
this distance and conformational changes are max-
imally discovered at a distance giving 50% of the 
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maximal transfer efficiency. So far it has not been 
possible to safely distinguish heterodimers vs. het-
eromers nor to quantitate the proportion of mono-
mers vs. heterodimers/heteromers with the FRET 
technique.
FRET experiments have mainly been made with 
fluorimetric analysis on suspensions of living cells 
distributed into wells of microplates read in a fluo-
rimeter [25]. Acceptor bleaching FRET with confo-
cal microscopy on fixed cells plated on coverslips 
adds the advantage of allowing studies on FRET in 
various domains of the cell like the plasma mem-
brane [25,49]. The FRET is shown by the rise of the 
emitted donor fluorescence after photobleaching 
of the acceptor since energy transfer cannot take 
place and instead the saved energy is spent as in-
creased fluorescence output from the donor. The 
FRET efficiency is calculated as 1 minus the ratio of 
donor fluorescence before and after photobleach-
ing of the acceptor and normalized to a scale from 
0 to 1. These experiments also represent impor-
tant controls for FRET experiments with fluorimetry 
since exogenous light sources can result in back-
ground signals that may be believed to be FRET 
signals [43]. Photobleaching fluorescence resonance 
energy transfer microscopy can also be performed 
by bleaching of the donor involving determination of 
histograms of time constants obtained from single-
exponential fits to pixel-based photobleaching decay 
curves [49]. The presence of acceptor leads to larger 
donor photobleaching time constants.
Time-resolved FRET can be used to establish 
FRET between receptors at the plasma membrane. 
N-terminally epitope-tagged GPCRs are employed 
and can be reached by the corresponding antibod-
ies in intact cells labeled with suitable FRET pairs 
[43,48,50]. By using Europium as an energy donor 
time-resolved FRET can be used since shortlived 
autofluorescence can decay during a period of 50 μs 
after which measurements of the long lived FRET 
signals can take place in periods of 100 to 400 μs 
[50,51]. This method is of substantial help in clari-
fying that the GPCR heterodimer/heteromer in fact 
exists in the plasma membrane of living cells and 
not only in the cytoplasm. However, there exist 
concerns that the antibodies used in time-resolved 
FRET may promote the oligomerization and inter-
fere with the ligand binding to the oligomer [43].
Measurements of FRET by fluorescence lifetime 
microscopy in living cells involving time correlated 
single-photon-counting with a picosecond diode pulse 
laser have given safe quantitative results on FRET 
signals. The measurements of fluorescence lifetime 
are in the nanosecond range, and are reduced by 
the existence of FRET [52]. It should be noted that 
the measurements are independent of changes in 
fluorophor concentration and in excitation intensity 
offering reliable information on the existence of 
heterodimers/heteromers.
A small, membrane−permeant fluorescein deriv-
ative with two arsen-(III) substituents (fluorescein 
hairpin binder, FLAsH) targeted to a short tetra-
cysteine sequence has been inserted to GPCR and 
used in a FLAsH based FRET approach to follow G 
protein activation in living cells [53]. The CFP/
FLAsH-tetracysteine system in contrast to the CFP/
YFP tagged to the A2A receptors did not block the 
AC activation and gave higher FRET signals under-
lining the usefulness of this system to determine 
GPCR activation. Today intramolecular FRET has 
been developed by Lohse and his group as a first 
choice method to monitor receptor signaling in 
space and with time in intact cells [54,55].
2.2. BRET
Bioluminescence resonance energy transfer (BRET) 
is similar to FRET and is a process in which the 
donor is bioluminescent and the acceptor is fluo-
rescent. It demands that the emission spectrum of 
the donor and the excitation spectrum of the ac-
ceptor overlap and the existence of a less than 10 nm 
distance between the donor and the acceptor. The 
luminescence is a phenomenon taking place natu-
rally in various marine animals like the sea pancy 
Renilla reniformis (Rluc). In BRET the luminescence 
obtained from the luciferase substrate coelentera-
zine H (BRET1) when bound to Rluc (emission peak 
at 470 nm) is transferred to a variant of green fluo-
rescent protein, so called enhanced yellow fluo-
rescent protein (eYFP), which then in the case of 
the existence of dimerization emits fluorescence in 
its well known spectrum (emission peak at 530 nm). 
Therefore, the ratio between emission at 530/emis-
sion at 470 is increased. The BRET signal is meas-
ured by dividing the amount of yellow light from YFP 
by the amount of blue light. The versatility of this 
technique has become enhanced by constructing 
fusion proteins where the two tags are added ei-
ther to the N-terminal or the C-terminal of the two 
GPCR’s analyzed for BRET. The strict requirement 
for molecular proximity makes it an important tech-
nique for detecting homo and heteromerization.
Unlike FRET, BRET is not sufficiently sensitive 
to be used for single cell signaling and thus not ca-
pable to give information on subcellular locations 
of the signals but has the advantage over FRET of 
lack of potential direct excitation of the acceptor 
reducing the disturbances from background signals 
[43,48]. To further reduce background signals the 
Renilla luciferase substrate DeepBlueC can be used 
with an oxidation spectrum having an emission peak 
at 400 nm (BRET2) which can effectively activate 
the acceptor GFP2 giving a fluorescence emission 
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with a peak at 510 nm having little overlap with the 
Rluc emission.
The introduction of the “saturation” BRET was 
an important development in the BRET field [43,56] 
showing that a saturation curve could be obtained 
by increasing the acceptor/donor ratios similar to 
those observed in ligand binding experiments. In 
this way a BRETmax value could be obtained de-
pendent on the number of heteromers and the ori-
entation of the Rluc and the acceptor fluorophor 
and BRET50 value giving the value of the half-maximal 
signal giving information on the relative affinity of 
the interactions between the two participating 
GPCRs tagged for BRET [25].
In 2006 a novel approach to BRET was introduced 
to better separate BRET signals arising from ran-
dom interactions at the plasma membrane vs. those 
occurring in homo or heteromeric proteins like 
receptor homo or heteromers [57]. This was made 
possible by the use of two types of experiments 
(Type-1 and Type-2). Type-1 experiments involve the 
analysis of BRET efficiency at a fixed surface den-
sity and varying the acceptor/donor ratio. In this 
case molecules that oligomerize show an increased 
BRET efficiency as the ratio increases since the do-
nors and acceptors compete in forming oligomeric 
complexes. Type-2 experiments involve varying the 
expression levels at a fixed acceptor/donor ratio 
[57]. In this case constitutive homo-heteromers pro-
duce a BRET efficiency that is unaltered by changes 
in surface density since folding and complex forma-
tion are not affected by this parameter in contrast 
to monomers that show an increase in the likelihood 
of BRET efficiency due to random interactions [57]. 
However, these experiments also have pitfalls as 
discussed by Bouvier et al [58] and Salahpour and 
Masri [59].
These groups [59,60] and others [61] have, how-
ever, shown that type-2 experiments are in fact 
useful for demonstrating oligomers of class A GPCRs 
like beta2 adrenergic homodimers and D1 or D2 
homodimers. Thus, the slope between BRET signals 
and receptor expression levels is zero and therefore 
the BRET signal cannot be due to random molecular 
interactions but to the formation of homodimers 
[59]. This contrasts with results from the type-2 ex-
periments performed by James et al [57] who im-
plied that BRET signals for class-A GPCRs are a result 
of random interactions. The experimental design of 
their type-2 BRET experiments may, however, be in-
correct which became apparent from the concerns 
raised by Salahpour and Masri [59].
Finally, it should be noted when performing 
BRET and FRET that the fluorescence or biolumines-
cence signal per GPCR binding site varies from one 
GPCR to the other, which may possibly be related 
to differences in folding rates between the catalytic 
site of the Rluc or the fluorophor and the binding 
site among different GPCRs. Therefore, the sensi-
tivity of the BRET and FRET procedure may depend 
on the GPCRs involved [43].
2.3.  Limitations of the BRET-FRET 
techniques
Recently, however, it has been pointed out that 
pitfalls still remain with the BRET and FRET tech-
niques since energy transfer between the two fluo-
rescent moieties can take place when a tight dimer 
exists or when the receptors are more than 50 nm 
apart [62]. Thus, the molecular proximities can be 
reported but it is difficult to absolutely prove the 
direct physical interactions between two GPCRs. 
Nevertheless, most researchers have accepted their 
existence in cotransfected cell lines based on these 
biophysical techniques including also bimolecular 
fluorescence complementation (BiFC) [63,64] es-
pecially when energy transfer can be demonstrated 
in physiologically relevant expression levels and the 
problem of “crowding” is avoided. In the case of 
class C receptors there is no doubt that they exist as 
homo and heterodimers since the covalent bonding 
(disulfide bridges) of non-heptahelical domains is 
sufficiently strong through its high affinity to give 
an energetically acceptable mechanism for stable 
dimer formation [65]. The case of class A receptors, 
however, is more controversial. It has recently been 
proposed that the bonding may not have the bind-
ing energy necessary for stable dimers but may only 
allow transient “kiss-and-run” encounters. Instead 
a dynamic equilibrium between monomers and dim-
ers of varying stability may exist [65]. However, the 
high energy strength of the electrostatic arginin-
phosphate salt bridges has not been considered in 
this proposal (see below).
In understanding the existence and size and 
stability of receptor dimers and RMs it becomes im-
portant for the future to use site directed spin label-
ing and distance measurements by pulsed electron 
paramagnetic resonance (double electron-electron 
resonance, DEER) [62].
The major problem in the field is, however, the 
identification of the heterdimers and RMs in native 
brain tissue since here it is more difficult to use 
the BRET and FRET techniques. There is a need to 
introduce the generation of transgenic mice express-
ing receptor pairs or trimers tagged with different 
variants of GFP in order to perform confocal FRET 
based techniques in brain tissue and in this way 
identify the heterodimers and RMs. This approach 
involves also the use of GFP tagged mutant recep-
tors that cannot heteromerize in cell lines in this way 
obtaining negative controls. So far mainly indirect 
techniques have been used to obtain indications 
6 K. Fuxe et al
for their existence in native brain tissue like coim-
munoprecipitation. Furthermore, ever since the early 
1980s the discovery of large numbers of intramem-
brane antagonistic and facilitatory receptor-receptor 
interactions, studied especially at the recognition 
level [8,10] have given indications for the existence 
of different types of receptor heterodimers and 
RMs in various regions of the brain. These receptor-
receptor interactions have successfully been inter-
preted as reflecting the existence of allosteric 
mechanisms operating over the interfaces of recep-
tor heterodimers and RMs leading to an integrated 
and coordinated signaling to various effectors like 
ion channels, kinases and phosphatases giving rise 
to a fine-tuned and dynamic regulation of neuronal 
excitability, firing and gene expression. Presently 
in the field experiments are being performed to 
obtain irrefutable evidence that the intramembrane 
receptor-receptor interactions demonstrated in na-
tive brain tissue are linked to direct physical receptor-
receptor interactions in heterodimers and RMs and 
not represent indirect receptor-receptor interactions 
mediated via inter alia adapter proteins.
2.4.  Determination of the receptor mass in 
protein-detergent complexes by size 
exclusion chromatography (SEC)
It is of substantial interest that the purified neuro-
tensin receptor 1 NTS1 belonging to class-A GPCRs 
can dimerize in detergent solutions in a way which 
is concentration dependent and has a high affinity 
(low nanomolar concentrations) [66]. SEC was used 
with light scattering, refractive index and ultravio-
let measurements to determine the molecular mass 
and homomeric state of the membrane proteins, 
which at the lowest concentrations of 1 nM and below 
show NTS1 existing as a monomer. This study to-
gether with the study on the leukotrien B4 receptor 
BLT1 [67] give further evidence that class-A GPCRs 
can dimerize and that the dimers formed develop 
allosteric interactions as shown in the case of the 
NTS1 dimer by the demonstration of positive coop-
erativity in the NT binding [66]. NTS1 dimerization 
was found not to be essential for G protein coupling 
with the NTS monomers activating the Gαqβ1γ2 more 
efficiently and β2 adrenergic receptor monomers in 
lipid discs also produce an effective activation of 
G proteins [68−70]. In fact, in solution the monomeric 
GPCR rhodopsin activates its G protein transducin at 
the diffusion limit giving evidence that an activated 
rhodopsin monomer is sufficient for a full G protein 
activation [71]. The reduced efficiency of the NTS1 
dimer to activate the Gαq was interpreted to reflect 
a result of an occlusion of one of the G protein sub-
unit binding sites in the receptor dimer leading to 
internal competition for binding [66].
Using a novel flow cytometric FRET analysis 
combined with a 2 step approach it was possible 
to demonstrate serial transfer of energy from CFP 
to YFP to HcRed demonstrating that tumor necrosis 
factor receptor associated factor (TRAF) 3 can form 
heterotrimers with TRAF2 modulating its ability to 
produce NF-κB activation [72].
Recently it has been possible by means of a 
novel technique, the so-called sequential BRET-
FRET technique, to obtain indications for the ex-
istence of trimeric RMs of A2A-CB1-D2 receptors in 
cotransfected cell lines [73]. Furthermore, a com-
bined BRET-BiFC has been developed giving sup-
port for the existence of RMs built of at least three 
A2A receptors in living cells [63]. With biolumines-
cence/fluorescence complementation and energy 
transfer also at least four dopamine D2 receptors 
have been shown to be located in close molecular 
proximity in living cells likely forming RMs of four 
D2 receptors [64].
With atomic force microscopy Palczewski, Fotiadis 
and colleagues [74] could even obtain indications 
that rhodopsin exists as high order arrays of dimers 
in the native disc membrane in the retina having a 
paracrystalline arrangement. However, studies on 
rhodopsin diffusion in disc membranes are not com-
patible with such arrangements [75]. Also with this 
method in combination with immunogold technique 
indications have been obtained that in CHO cells 
stably transfected with human D2L receptors, RMs 
of D2L receptors may be formed with a ring struc-
ture [76]. The existence of a closed loop RM (ring 
model) of GPCRs had previously been postulated 
[77] based on interactions between the 5 and 6 TM 
domains and domain swapping [30].
3.  The receptor interface among 
GPCR RMs
In the case of the GABAB receptor, which belongs 
to the family class C of GPCRs and is an obligate 
heterodimer, the interface is mainly formed by the 
TM domains and coiled-coil interactions in the 
C-terminal tails of the GABAB1 and GABAB2 receptor 
subunits [34]. This was in fact the first demonstra-
tion of a heterodimer among the GPCRs and took 
place in 1998/1999. The mGluR5 and mGluR1 re-
ceptor were instead shown in 1996 and 1998 to be 
disulfide-linked homodimers, respectively [32,78] 
with the interprotomer disulfide bridge existing in 
the large extracellular domains. The crystal struc-
tures of the ligand binding regions of the mGluR1 
show that glutamate binds to the crevice (venus 
flytrap domain; VFT) of the two binding domains 
[79]. The glutamate binding results in a rearrange-
ment of the VFP which via an allosteric mechanism 
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is transferred to the heptahelical effector domain 
leading to a transduction of the glutamate induced 
conformational change in the binding pocket to 
the G protein as shown with FRET [80]. Thus, both 
intracellular and extracellular domains are involved 
in the dimeric interface [10,81]. Also the sweet and 
umami taste receptors belonging to the class-C of 
GPCRs have been shown to be functional only when 
forming heterodimers [82−84]. The sweet receptor 
is formed from T1R2 and T1R3 and the umami re-
ceptor from T1R1 and T1R3. Thus, the dimer is 
probably required in this class of GPCR for the trans-
fer of the conformational change from the extra-
cellular agonist binding pocket to the heptahelical 
TM domains [85].
It has been found, that it is more difficult to 
identify the TM domains that interact in various 
heteromers. The first studies in 1996 by Bouvier 
et al [31] on the β2 adrenergic receptors indicated 
that TM6 was involved since peptides from the TM6 
domain, but not the mutated TM6 peptides blocked 
the dimerization. The first TM interaction to be dem-
onstrated among the GPCRs was the one between 
the two TM4 domains in the interface of the D2 
homodimer [86] and to-day most TM domains have 
been implicated in the dimeric interactions among 
class-A GPCRs [87,88].
In the beginning only contacts between TM heli-
ces (contact dimers) were considered but based on 
the functional rescue studies of Maggio et al [28] 
on chimeric (mutant) muscarinic-adrenergic recep-
tors, Reynolds, Gouldson et al [30,87] introduced 
the model of domain swapping at the TM5 and TM6 
interface based on molecular modeling and bioin-
formatics. It has also been possible to reconstitute 
the binding site of two deficient mutants of the 
type 1 angiotensin II receptor [29] and domain swap-
ping has been demonstrated in the histamine H1 
receptor but only from functionally impaired re-
ceptors [89]. It has also been proposed that both 
domain swapping and domain contact can take place 
(mixed−model dimer) allowing the possible assem-
blage of high order GPCR (RMs) into a ring struc-
ture (closed loop) [77]. Indications of the existence 
in cell lines of ring-like structures of D2 homomers 
have recently been obtained with atomic force mi-
croscopy [76]. In a classical paper by Palczewski, 
Fotiadis and colleagues [74] indications were ob-
tained with atomic force microscopy of a paracrys-
talline arrangement of rhodopsin dimers in native 
disc membranes [90].
The pioneering work of Amina Woods [91] gave 
evidence of a fundamental role for electrostatic 
epitope-epitope interaction in the formation of 
the interfaces between proteins leading to the 
assemblage of the protein and RMs, which will be 
discussed below.
3.1.  Electrostatic epitope-epitope 
interactions in RMs
Electrostatic interactions between an arginine rich, 
highly conserved epitope (basic motif), found in the 
third intracellular loop of Dopamine D2, D3 and D4 
receptors, and a phosphorylated serine/threonine 
(acidic motif) on the C terminal tail of the Adenosine 
A2A receptor (Figure 1) are involved in the A2A/D2 
receptor heteromerization [92]. This was demon-
strated with mass spectrometry and confirmed in bi-
ochemical pulldown assays. The arginine-phosphate 
electrostatic interaction possesses “covalentlike” 
stability [93]. Hence, these bonds can withstand frag-
mentation by mass spectrometric collision-induced 
dissociation at energies similar to those that frag-
ment covalent bonds and they show very slow dis-
sociation of the noncovalent complex by plasmon 
resonance. The work also highlights the importance 
of phosphorylation-dephosphorylation events in the 
modulation of electrostatic attraction. Phosphoryla-
tion of the acidic motif by casein kinase on one re-
ceptor makes it available for interaction with the 
basic motif on the other. On the other hand, phospho-
rylation of serine and/or threonine residues down-
stream from the basic motif, by protein kinase A or 
C slows down the attraction between the epitopes. 
Although analyzed here in the frame of receptor 
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Figure 1 Illustration of the electrostatic epitope-epitope 
interactions in the intracellular parts of the A2A-D2 
heteromers (seen in the box). Two epitopes with nega-
tive charges (in bold) exist in the C terminal tail of the 
A2A receptor, the one with the phosphorylated serine 
(SAQEpSQGNT) being of special interest, since it under-
lines the role of phosphorylation processes in the elec-
trostatic interactions. Positive charges (in bold) exist in 
the arginine rich epitope (VLRRRRKRVN) in the N terminal 
part of the intracellular loop 3 of the D2 receptor which 
interacts with the negatively charged epitopes seen in 
this figure. These non-covalent interactions in the intra-
cellular part of the two receptors are strong and repre-
sent an important part of the A2A/D2 interface (see text 
for references).
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heteromerization, the arginine-phosphate electro-
static interaction most likely represents a general 
mechanism in protein-protein interactions [45].
3.2. On the role of disordered domains
Based on the discovery of strong salt bridges be-
tween the guanidinium groups of arginines in the N 
terminal part of the IC loop 3 of the D2 receptor 
and the phosphorylated serine of the C-terminal 
tail domain of the A2A receptor [45,92] we became 
very interested in understanding the structural 
plasticity on the IC loop 3 and the C-terminal tail and 
also other domains of the GPCRs [94]. One form of 
receptor plasticity is the so called structural mal-
leability related to the ability to interact with mul-
tiple protein partners [95]. Such properties are often 
dependent on the existence of disordered sequences 
of amino acids without a rigid secondary structure. 
The random coil is the typical disordered state. It 
should be considered that the fluctuations of the 
conformational states in the receptors of a RM are 
in fact conditioned by the conformations of the other 
participating receptors. The assemblage of RMs may 
inter alia take place via reciprocally induced-fit 
interactions between two malleable domains of 
two GPCRs [94]. It therefore becomes of substan-
tial interest to detect the location of various disor-
dered sequences in the domains of GPCRs since they 
are probably located in strategic positions for the 
development of receptor-receptor and receptor-
protein interactions.
Computer-assisted analysis of amino acid se-
quences in 14 different GPCRs has been performed 
with 10 different computer-assisted programs to de-
termine flexible and malleable domains [14,94,96]. 
A global index of disorder (DI) has been obtained 
by pooling the results from for the major GPCR do-
mains including N-terminal, extra and intra cellu-
lar loops, TM helices and C-terminal of the 14 GPCRs 
examined. The DI of a domain was calculated on the 
basis of the number of disordered amino acids vs. 
the total number of amino acids in that domain.
The disorder index of the domain representing 
postgenomic plasticity was compared with coeffi-
cient of variation (CV) of the number of amino acids 
(length of chain) in that domain among the 14 GPCRs 
analyzed, representing genomic plasticity.
It is of substantial interest that the N-terminal, 
IC loop 3 and C-terminal domains have both the 
highest disorder index and highest coefficient of 
variation showing that postgenomic and genomic 
plasticity go together. In view of our special interest 
in the A2A/D2 heteromer, the A2A and the D2 recep-
tors were included in the present computer assisted 
analysis [94] and thus we can state that the power-
ful electrostatic interactions demonstrated between 
the D2 IC loop 3 and the A2A C-terminal domains 
may be made possible by the high structural plas-
ticity of these domains. In fact, the disorder index 
of D2 IC loop 3 was high (0.620) as was the disorder 
index of A2A C-terminal domains (0.613).
It may be stated that in the assembly of RMs, the 
receptors with many disordered domains may be the 
hub receptors, by interacting directly and at the same 
time with several participating receptors [97,98].
3.3. 3D model building of dimeric RMs
Early on in 2003 computational experiments were 
performed on the A2A/D2 heterodimeric RM by 
Fanelli and colleagues to generate a hypothesis on 
its interface [25]. It was based on docking simula-
tions on theoretical models of A2A and D2 receptors. 
The whole sequences of the two receptors were 
modeled since the interface may also involve the 
intracellular and/or extracellular domains as sug-
gested for rhodopsin [99]. Nine different average 
minimized structures of the A2A receptor were 
employed and each of them docked to the selected 
average minimized structure of the D2 receptor. Two 
different rigid-body docking programs ZDOCK and 
ESCHER were utilized resulting in a total of 32,000 
and 9,400 filtered solutions which were markedly 
reduced upon additional filtering. Most realistic dock-
ing solutions revealed that the interface contained 
D2 portions including the C-terminal half of helix 5 
and the N-terminal portion of IC3 with stretches of 
positively charged amino acids especially arginines 
[25]. Two sets of dimers with similar interfaces in 
each set were obtained. In the most populated dimer, 
helix 5 and/or helix 6 of the D2 receptor approach 
helix 4 of the A2A receptor and the N-terminal part 
of the IC3 domain of the D2 receptor approach the 
C-terminal portion of the C-tail of the A2A receptor 
validated by the results of the BRET experiments 
on the chimeric D2R-D1R and the A2A receptors.
This computational protocol has been further 
improved for the prediction of the supramolecular 
organization of the TM alpha helical proteins by 
rigid-body docking [25,100]. Such computational 
modeling including also ad hoc filtering, automatic 
cluster analysis and visual inspection of cluster 
centers have been employed to predict the inter-
face of lutropin homodimers [101]. The results hy-
pothesize the importance of helix 4, 5 and 6 and 
especially helix 4 in the inter-monomer interaction 
of this dimer along the lines of sequence based pre-
dictions [102] and may take place via weak Van der 
Waals interactions between hydrophobic amino 
acids. In this case the hydrophilic loops appear to 
play only a minor role and mutation induced lutro-
pin receptor activation lead to increased contacts 
between helix 4-helix 4 of the lutropin dimer [101].
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This computational approach has also recently 
been employed to hypothesize mechanisms of inter 
and intramolecular communication in GPCRs and G 
proteins [103].
4.  Cooperativity in RMs as a 
molecular mechanism for the 
receptor-receptor interactions
It has been proposed that classical cooperativity 
plays an important role in the decoding of signals 
in RMs of GPCRs built up of homomers or of isorecep-
tors (receptor subtypes for the same transmitter) 
involving allosteric mechanisms with ligand induced 
conformational changes in one receptor passing via 
the interfaces to the other receptors [8,76,103]. 
This leads to alterations in the binding properties 
and G protein coupling of the adjacent receptors 
in the RM and is the major molecular mechanism 
for the intramembrane receptor-receptor interac-
tions. The same principle molecular mechanism also 
mediates the intramembrane receptor-receptor in-
teractions in RMs built up of heteromers but in view 
of the fact that the binding sites of the participating 
receptors are different the term for this type of 
cooperativity should be non-classical cooperativity 
[14,94,96]. The receptor monomers themselves in 
the absence of transmitters when binding to their 
receptor partners in the RM can be allosteric mod-
ulators and produce non-classical cooperativity in 
the RM involving not only the receptor recognition 
but also G protein coupling and the assemblage of 
the RM.
4.1. Dimer-based model of GPCR
The two state dimer receptor model can readily ex-
plain the nonlinear Scatchard plots for agonist bind-
ing to GPCRs since it predicts cooperativity in binding 
[104,105]. The model can explain both negative and 
positive cooperativity giving concave downward and 
upward Scatchard plots, respectively.
It is true that the fitting to the “two-state dimer 
model” was similar to that to the “two-independent 
site model” assuming two types of conformational 
states of the receptor. However, the two-state dimer 
model has less parameters and is therefore the 
simplest model to explain the binding results.
The ligand-binding process in the dimer-based 
model is strongly influenced by the binding coop-
erativity (μ) between the first and second A mole-
cule to the A homodimer where A is the ligand. This 
is true also for the constant α reflecting the intrin-
sic efficacy of A and the constant θ reflecting the 
intrinsic efficacy of the second A molecule binding 
to the dimer. The appearance of the Scatchard plots 
is highly dependent on these values; high values of 
μ and low values of α as indicators for positive co-
operativity, and low values for both μ and α as indi-
cators for negative cooperativity (concave downward 
Scatchard plots). With a high value of θ positive 
cooperativity is mainly found. The two-state dimer 
model clearly demonstrated positive cooperativity 
for agonist binding to estrogen receptors known to 
show positive cooperativity [104]. Thus, this model 
may become a general model for receptor dimers 
and it also predicts the various responses of full and 
partial agonists, neutral antagonists and inverse 
agonists [106].
5.  Altered recognition in receptor 
heterodimers and RMs gives 
unique pharmacology
In the case of class C GABAB receptors it became 
clear in 1998 that it is an obligate heterodimer 
formed from two GABAB receptor subtypes, GABAB1 
and GABAB2 [34,107]. The GABAB1 gives the bind-
ing and GABAB2 the signaling. This was the first 
demonstration of a heterodimer and had a major 
impact on the field of receptor-receptor interac-
tions. The same appears to be true for other class 
C GPCRs and dimerization in fact produces the re-
ceptor by enabling the signal to pass from the fly-
trap domain of the GABAB1 receptor in the large 
extracellular region to the TM domain of the GABAB2 
receptor via allosteric mechanisms. It has also in 
fact been shown that the GABAB2 receptor hepta-
helical domain expressed alone can signal after 
activation by a positive allosteric activator of the 
GABAB receptor, CGP7930 [108].
Recently the D1-D2 receptor heteromer has been 
discovered in brain by means of coimmmunoprecip-
itation and identified as a neuronal Gq/11 coupled 
heteromer with a unique pharmacology by the 
George group [109,110]. It was found that the D1 
agonist SKF83959 was a selective agonist for this 
RM by being a full agonist at the D1 receptor partner 
and a partial agonist at the D2 receptor existing in 
a pertussis insensitive state leading to rapid acti-
vation of Gq/11 and phospholipase C with a robust 
intracellular release of calcium. It should be under-
lined that the D1 like agonist SKF83959 does not 
activate AC linked D1 or D2 receptors and may there-
fore be a unique agonist for the D1-D2 RM. Thus, 
this work represents an interesting example of how 
the RM field may generate new drugs in neuropsy-
chopharmacology [14]. A diminished link between 
D1 and D2 receptors has been demonstrated in the 
striatum of schizophrenic patients [111] and the cal-
cium signaling mediated increases in CaMKIIalpha 
is required for the sensitization to cocaine [112].
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It is of substantial interest that the likely exist-
ence of α1B-α1D receptor heteromers may explain 
the disappearance of α1D receptors in native tis-
sue based on the disappearance of high affinity 
binding sites for the selective α1D antagonist BMY 
7378 [113]. Thus, the appearance of the α1B-α1D 
heteromer may result in a novel receptor in which 
the α1D binding pocket has become conformation-
ally altered to obtain markedly different pharma-
cological properties. In line with these results α1B 
knockout mice demonstrate an increased affinity 
for the α1D receptor antagonist BMY7378 [114]. The 
existence of this heteromer may also help explain 
the discrepancy between α1D mRNA levels and 
expression of functional α1D receptors [117].
Very interesting changes in the A1 receptor phar-
macology have been discovered by Nakata and his 
team in A1-P2Y1 receptor heteromers [115,116]. 
This heteromerization results in a conformational 
change in the A1 binding pocket leading to the ap-
pearance of an A1 receptor with P2Y like agonistic 
pharmacology. In fact, a P2Y1 agonist binds to the 
A1 receptor and produces an inhibition of AC which 
is blocked by an A1 antagonist. An ATP responsive 
A1 receptor has become generated that can be one 
mechanism for ATP induced inhibition of transmit-
ter release as it is released from nerve terminal 
networks.
Altered recognition in the individual GPCR re-
ceptor of receptor heteromers almost always takes 
place after exposure to agonists for the other par-
ticipating GPCR receptors as studied in membrane 
preparations and has been extensively reviewed 
[10]. This was the way the intramembrane receptor-
receptor interactions were discovered in brain mem-
brane preparations in 1980−1981 and indicated the 
existence of GPCR heteromers in which antagonis-
tic or enhancing, receptor-receptor interactions at 
the recognition level could be observed and made 
possible via classical or non classical cooperativity 
with conformational changes passing via the recep-
tor interfaces to the other receptor as discussed 
above. The receptor-receptor interaction gives a 
functional integrated outcome of the receptor 
heterodimer and the RM [5,8,14,76] the latter giv-
ing an improved nomenclature by underlining the 
importance not only of the stoichiometry but also 
of the topology of the different kinds of receptors 
involved.
6.  Alterations of G protein coupling via 
receptor-receptor interactions in RMs
It has been suggested that dimerization is at least 
sometimes required for an efficient receptor-G pro-
tein coupling [19,22] and dimers are preferentially 
expressed on the plasma membrane vs. monomers 
as inter alia demonstrated for the A2A homodimers 
[50]. It should be considered, however that the 
expression of a GPCR monomer is sufficient for G 
protein coupling [63−65] and the GPCR rhodopsin 
monomer activates its G protein transducin at the 
diffusion limit [71]. Also some dimers have been 
found to show reduced ability to activate G proteins 
vs. their respective monomers [61,63]. Nevertheless 
in 1999 Jordan and Devi [40] demonstrated that 
combined activation of the two receptors in the 
δ-κ opioid receptor heteromer was necessary for 
an optimal activation of this RM and a proper MAP 
kinase cascade activation only took place upon 
combined agonist activation of the two receptors. 
Furthermore, George et al [15] found that in the 
D1-D2 receptor heteromer phospholipase C activa-
tion and thus signaling only developed if the two 
participating D1 and D2 receptors became acti-
vated [15,109,110].
On the other hand, a single agonist per mGluR 
homodimer gives signaling even if full activity de-
mands two agonists per dimer [117]. Also Milligan’s 
group has demonstrated transcomplementation be-
tween two class A GPCR defective in ligand binding 
or G protein coupling. Thus, agonist binding to one 
receptor of a dimer can give rise to substantial sig-
naling [118,119]. Such a nonsymmetric activation 
of dimers is also in line with the demonstration of 
negative cooperativity in agonist binding as shown 
first by Lefkowitz and colleagues [4]. Negative co-
operativity has now been shown to take place in 
heterodimers of chemokine CCR2 and CCR5 recep-
tors and in glycoprotein hormone receptor dimers 
[120,121].
It is therefore of substantial interest that asym-
metric conformational changes have been observed 
in a leukotriene B4 receptor dimer controlled by G 
proteins [67]. The fluorescent properties of the 
dimer were measured based on a single 5-hydroxy-
tryptophane labeled protomer and a single agonist 
per dimer caused full G protein activation. Also 
when the two receptors bind the agonist the con-
formational state of the two receptors differs in 
the presence but not in the absence of G protein. 
Thus, the G protein may mediate the asymmetric 
function of the dimer by altering the energy land-
scape of the second receptor. In the paper, an excit-
ing theory is introduced inferring that the symmetric 
dimer instead is associated with arrestin and that 
stoichiometry of receptor activation in the RM may 
contribute to the selection among signal pathways 
available to the RM [67].
The D1-D2 receptor heteromer is an example of 
how the formation of a heteromer will switch the 
coupling of participating receptors to other G pro-
teins [122]. In this case both the D1 and D2 receptors 
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become coupled to rapid activation of Gq/11 in the 
striatum instead of Gs and Gi/o respectively and 
the Gq/11 activation requires agonist binding to 
both the D1 and D2 receptors. In this way the 
PLC can become activated leading to intracellular 
calcium release and increased levels of calcium/
calmodulin-dependent protein kinase IIα contrib-
uting to synaptic plasticity [109]. This represents 
an interesting example of how the formation of RMs 
increases the diversity of signaling pathways that 
can be used by receptor subtypes, in this case DA 
receptor subtypes and thus their functional reper-
toire in the brain. Its dysfunction may contribute 
to neuropsychiatric disease.
In the period 1968−1974 Anden, Corrodi and 
Fuxe and colleagues introduced the theory that a 
postjunctional 5-HT receptor in the brain may medi-
ate the hallucinogenic effects of d-LSD, psilocybin 
and other hallucinogenic drugs of the indolalky-
lamine and phenylamine type based on studies on 
5-HT turnover and 5-HT receptor activity [123−125]. 
This postjunctional 5-HT receptor has now been 
identified as the 5-HT2A receptor, enriched in layer 
IV of the cerebral cortex [126,127] since hallucino-
gens can recruit cortical 5-HT2A receptor medi-
ated signaling pathways to affect behaviors [128].
Recently the exciting discovery has been made 
by Gonzalez-Maeso, Milligan and colleagues that 
5-HT2A receptors form a RM with mGluR2 via TM 
helices 4 and 5 of mGluR2 in the brain cortex [129]. 
This RM may be the major target for hallucinogenic 
drugs since it allows the hallucinogenic 5-HT2A ag-
onists to produce conformational changes in these 
5-HT2A receptors in such a way that they become 
able to activate not only Gq/11 but also the Gi/o 
protein and its signaling pathways, necessary for 
their hallucinogenic effects [128]. This is another 
example of how unique conformational changes 
may develop in a receptor of a RM altering its pat-
tern of G protein coupling in response to special 
agonists as a result of allosteric mechanisms oper-
ating via the receptor interfaces.
In this paper, it is also beautifully demonstrated 
that activation of mGluR2 antagonizes the 5-HT2A 
mediated hallucinogenic signaling in this RM via 
non-classical cooperative interactions at the rec-
ognition and G protein coupling level. In fact, 
there exist findings suggesting that they have an 
antischizophrenic potential [130,131]. This fine 
work of Gonzalez-Maeso, Sealfon, Milligan and col-
leagues [129] gives a novel target, the 5-HT2A-
mGluR2 RM, for anti-schizophrenic drugs present 
in the cortical networks, especially in layer IV and 
involved in sensory processing. In this work they 
also report that in the schizophrenic brain the 
5-HT2A receptors are increased and the mGluR2 
reduced. It illustrates well the great impact the 
RMs and their receptor-receptor interactions will 
have for neuropsychopharmacology [14].
Alterations in G protein coupling have also been 
described for A2A-CB1 receptor heteromers [132] 
and for δ opioid receptor-μ opioid receptor heter-
omers compared the one observed with the indi-
vidually expressed receptors like a switch from Gi 
to Gs [133].
7.  Alterations in receptor trafficking 
and internalization via receptor-
receptor interactions in RMs: 
relationship to desensitization
7.1. Receptor trafficking
One of the first observations that GPCR dimeriza-
tion is important for receptor folding and transport 
to the plasma membrane came from the studies on 
the GABAB receptor in 1998 by several groups, the 
first heterodimer to be demonstrated [134]. The 
coexpression of the two isoforms of the GABAB re-
ceptor, GABABR1 and GABABR2, was found to be a 
prerequisite for the formation of a functional GABAB 
receptor at the cell surface. Thus, the GABABR1 is 
retained intracellularly as an immature protein if 
not expressed with GABABR2, while the latter iso-
form when expressed alone can be transported to 
the surface but cannot bind GABA. In fact, GABAR2 
serves as a chaperone essential for the proper 
folding and cell-surface transport of GABAR1 [36]. 
The molecular mechanism responsible is the coiled-
coil interaction of the carboxyl tails of the two 
GABABR isoforms leading to the heterodimeriza-
tion which leads to the masking of the ER-retention 
signal thereby allowing ER transport and surface 
membrane targeting of the heterodimer [36]. Also 
for β2-adrenoceptors belonging to the group-A 
GPCRs dimerization is a prerequisite for delivery to 
the plasma membrane [134]. It appears that dimer-
ization is an early event in receptor maturation and 
transport and intracellular retention of dimers oc-
curs when truncated forms of V2 vasopressin and 
CCR chemokine receptors are expressed [135,136]. 
It has been demonstrated that oxytocin and vaso-
pressin V1a and V2 form homo- and heterodimers 
during biosynthesis [22,137]. The need for dimers 
to reach the plasma membrane may stem from the 
indications that dimers can correspond to the major 
functional GPCR signaling unit engaging heterot-
rimeric G proteins. As an example, it should be men-
tioned that Canals et al [50] demonstrated that the 
A2A homodimers are preferentially expressed at 
the cell surface based on cell surface biotinylation 
of proteins followed by SDS-PAGE and immunoblot-
ting with 90% of the cell surface receptor being in 
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the dimeric form. Furthermore, increasing evidence 
indicates that class A GPCR dimeric and high order 
RMs biogenesis occurs at an early time point during 
receptor biosynthesis and maturation in the ER and 
Golgi having a potentially important role in the qual-
ity control of newly synthesized receptors [138]. 
Also “non-obligatory” heterodimers in the plasma 
membrane display pharmacological and functional 
characteristics different from those of their con-
stitutive monomers [139].
7.2. Internalization
A1-D1 RMs with antagonistic A1/D1 receptor inter-
actions have been demonstrated in cell lines and 
in striatum [7,41,140−142]. It is of interest that in 
fibroblast cells and cortical neurons in culture A1 
receptor agonists produced a coaggregation of A1 
and D1 receptors suggesting movement and aggre-
gation A1/D1 heteromers in the plasma membrane 
possibly associated with a certain degree of cointer-
nalization [41]. This coaggregation was blocked by 
combined treatment with A1 and D1 agonists which 
was associated with a D1 receptor desensitization 
at the 2 hours time interval. The mechanism for the 
D1 desensitization may be that coactivation will 
make possible the full development of the antago-
nistic A1/D1 receptor interaction with uncoupling 
of the D1 receptor from the Gs protein and the dis-
appearance of the high affinity D1 agonist binding 
site with maintained heteromerization and no signs 
of A1/D1 internalization. Thus, prolonged A1 activa-
tion can cause enduring conformational changes of 
the D1 receptor via the antagonistic A1/D1 interac-
tions leading to reduced D1 signaling. D1 phospho-
rylation and the binding of β-arrestins to the D1 
receptor may also contribute. However, in the case 
of the D1-D2 heteromer where no antagonistic 
receptor-receptor interaction exists cointernaliza-
tion develops after coactivation [122]. D1 receptors 
have also been shown to diffuse in the surface 
membrane of spines where they can be trapped by 
activated NMDA receptors [143] contributing to the 
formation of the D1/NMDA RMs [144].
The failure of morphine to cause internalization 
of μ opioid receptors is regarded as one mecha-
nism for morphine tolerance since dephosphoryla-
tion and reactivation of the μ opioid receptors may 
only develop upon internalization [145]. In view of 
the existence of μ opioid receptor homodimers it 
has been suggested that the μ agonist DAMGO by 
binding to one protomer may enhance the inter-
nalization of the morphine occupied protomer and 
counteract morphine tolerance due to the cotraf-
ficking of the two protomers [146]. Cotreatment 
of animals with morphine and low amounts of 
DAMGO also resulted in the appearance of morphine 
analgesia without tolerance. Thus, the frequent 
existence of cotrafficking of homo and heteromers 
may be used in novel treatment strategies.
It should be noticed that A2A/D2 heteromers 
with antagonistic A2A/D2 receptor-receptor inter-
actions has a different trafficking profile from the 
A1-D1 heteromers after coactivation of their recep-
tors by longterm exposure to D2 and A2A agonists 
[25,147]. Thus, in D2 cotransfected neuroblastoma 
cells coactivation of A2A and D2 receptors led to 
coaggregation, cointernalization and codesensiti-
zation of A2A and D2 receptors. The A2A and D2 re-
ceptor functions are simultaneously altered which 
may help in understanding behavioral findings of 
cross-tolerance and cross-sensitization between D2 
agonists on one hand and adenosine A2A agonists 
or A2A antagonists on the other hand. It seems likely 
therefore that the trafficking properties among the 
various types of heteromers may vary considerably 
and no general rules for their trafficking behavior 
can be introduced.
Recently evidence for the involvement of 
caveolin-1 in the internalization process of A2A-
D2 RMs was studied by using computer-assisted 
image analysis [26]. In A2A-D2 cotransfected cells 
caveolin-1 colocalized with both A2A and D2 recep-
tors. Interestingly, either the A2A agonist CGS21680 
or the D2 like agonist quimpirole induced internali-
zation of caveolin-1, A2A and D2 receptors with a 
preferential internalization of A2A and D2 recep-
tors colocalized with caveolin-1. In contrast, the 
D2 antagonist stabilizes the D2 receptor and re-
duces the internalization of both the D2 and A2A 
receptors [148].
These results are indicative of the functional 
role of caveolin-1 in A2A-D2 cointernalization and 
thus in the permanence and plastic adjustments of 
A2A-D2 RMs in the plasma membrane and in the 
sensitization and desensitization of the participat-
ing receptors. The analysis in the above papers [26,
148] suggests that the A2A and D2 receptors inter-
nalize as a dimeric or high order RM in line with 
the early results obtained on the yeast alpha-factor 
pheromone receptor that homo-oligomers are the 
functional units of endocytosis [149].
8.  Agonist regulation of receptor 
heteromerization
In 2000 Rocheville et al [150] demonstrated with 
FRET analysis that SSTR5 exists as a monomer in 
the basal state but becomes a dimer upon agonist 
activation. Also an agonist induced heteromeriza-
tion of SSTR5 and SSTR1 was demonstrated and was 
subtype specific. Furthermore, with photobleach-
ing FRET microscopy a SSTR5-D2 receptor heteromer 
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was observed but only after treatment with either 
agonist or coactivation of the two receptors had no 
further action [49]. Agonist induced enhancement 
of energy transfer for β2 adrenergic receptors was 
observed the same year by Angers et al [151] and for 
gonadotrophin-releasing hormone and thyrotropin-
releasing hormone the following year [152,153]. An 
agonist promoted decrease of energy transfer has 
been reported for the CCK receptor related to an 
agonist dissociation of the CCK oligomers [154]. 
However, many of the RMs are constitutive and not 
agonist induced probably because they are formed 
in the ER and Golgi and then inserted in the sur-
face membrane as discussed above. This may pos-
sibly not be true for the agonist induced heteromer 
like the SSTR5/D2 that may be fully formed only in 
the plasma membrane upon agonist activation.
A2A-D2 RM is a clear example of a constitutive 
RM. The BRET signal was not even modified by the 
agonist-induced activation of the A2A or the D2 
receptor or by their coactivation in spite of being 
expressed on the plasma membrane [25]. These 
results also indicate that the coaggregation of A2A 
and D2 receptors described above after agonist 
treatment does not lead to a change in the distance 
between the two tags of the heterodimer in view 
of absence of a detectable change in the BRET sig-
nal. Failures of agonist induced alterations in FRET 
and BRET signals have also been observed for the 
yeast alpha factor receptor [155] and the human δ 
opioid receptor [51].
The agonist induced changes in BRET and FRET 
signals may sometimes be interpreted as increases, 
decreases or no changes in the amount of RMs. 
However, also other mechanisms may explain the 
observed changes in energy transfer. BRET and 
FRET efficacies vary with the 6th power of the dis-
tance between the donor and acceptor. Also the 
receptor activation with agonists is associated with 
conformational changes within the TM core of the 
GPCR [156] with changes in G protein coupling, re-
ceptor phosphorylation and arrestin translocation. 
These events may affect the relative distance and 
orientation of the energy donor and acceptor de-
pending on their position in the receptor and the 
structural features of each receptor. Therefore, it 
may often be difficult to interpret the agonist pro-
moted changes in energy transfer as a result of a 
change in receptor oligomerization.
A study of melatonin receptor homomers shows 
that ligand-promoted BRET enhancement represent 
specific ligand induced conformational changes of 
preexisting receptor homomers linked to the acti-
vation state of the receptors [157]. For these ho-
momers they deduced that the dimeric state was 
the constitutive one based on data fitting by adapt-
ing the dimer, trimer and tetramer model of energy 
transfer quenching in which the oligomeric state 
of a receptor could be deduced from an equation 
[157]. This work has continued and in 2004 Ayoub 
et al [158] demonstrated preferential formation 
of MT1-MT2 heterodimers with distinct receptor-
receptor interactions when compared with MT2 
homodimers, probably reflecting development of 
differential allosteric mechanisms between the bind-
ing sites in the heterodimers vs. the homodimers 
resulting in different alterations in cooperativity.
It is of substantial interest that the two chem-
okine receptors CCR2 and CCR5 have been shown 
to form homodimers and heterodimers with the 
heterodimers demonstrating receptor-receptor in-
teractions characterized by the existence of nega-
tive cooperativity between their two binding sites 
[120,159,160]. Macrophage inflammatory protein 1β 
is a selective agonist at CCR5 and monocyte chemo-
attractant protein-1 a selective agonist at CCR2. 
Furthermore, the CXCR4 is the cognitive receptor 
for the stromal cell-derived factor 1α which induces 
a dimerization of its receptor necessary for signaling 
[161]. In view of the existence of these chemokine 
receptors in brain tissue including the substantia 
nigra as agonist dependent homomers and heter-
omers it has been postulated that in acute neuroin-
flammation the chemokines and also cytokines via 
their respective receptors can produce the forma-
tion of novel pathological RMs or dysfunctional RMs 
including also other types of receptors not belong-
ing to the immune system [162−165]. This may be 
caused by the conformational changes induced in 
these immune receptors by the panorama of agonists 
present in the inflammatory brain regions which 
may lead to chronic neuroinflammation and neuro-
degenerative disease like Parkinson’s disease.
The hypothesis has also been introduced that the 
viral-coded receptors not only operate as constitu-
tively active monomers, but also can affect other 
receptor functions by interacting with receptors of 
the host cell forming novel pathological RMs with 
abnormal signaling [166]. Furthermore, it is sug-
gested that viruses could insert not only single re-
ceptors (monomers), but also dimeric or high order 
RMs, altering the cell metabolism in a profound way. 
The prevention of the formation of viral receptor—
host RMs with disease producing signaling may give 
rise to novel antiviral drugs that counteract virally-
induced disease.
9.  Role of allosteric modulators in the 
function of GPCR RMs
Previously it has been shown that homocysteine, a 
sulfur-containing amino acid formed by demethyl-
ation of methionine, can modulate NMDA receptor 
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function leading to increased NMDA receptor activ-
ity that may contribute to its neurotoxic effects 
[167]. Recently an allosteric modulation of D2 re-
ceptors has been demonstrated after homocysteine 
with lower concentration than those modulating 
NMDA receptor function [168]. The evidence ob-
tained in A2A-D2 cotransfected CHO cell lines sug-
gests that homocysteine acts as an allosteric D2 
receptor antagonist. It reduces the affinity of the 
D2 agonist binding sites and decreases the ability 
of D2 receptor activation to produce an internaliza-
tion of the A2A-D2 RM. Mass spectrometric analysis 
demonstrated that homocysteine forms noncova-
lent complexes with the two Arg-rich epitopes in 
the third intracellular loop of the D2 receptor one 
of them participating in the A2A-D2 receptor heter-
omerization. However, homocysteine could not pre-
vent nor disrupt the A2A-D2 heteromerization as 
shown in FRET experiments. Therefore, the allos-
teric antagonistic action of D2 receptor recognition 
and signaling (evaluated in behavioral experiments) 
by homocysteine may depend on its binding to the 
Arg-rich region in the middle portion of the IC loop 3 
of the D2 receptor leading to conformational changes 
causing reduction in recognition and G protein 
coupling [168,169]. The results indicate that this 
negative allosteric modulation may exist with 
maintained A2A-D2 heteromerization also inhibit-
ing D2 receptor recognition and signaling via the 
antagonistic A2A/D2 receptor-receptor interaction 
[7,170]. Thus adenosine and homocysteine extra-
cellular levels in brain may jointly act to silence 
D2 signaling and worsen the behavioral deficits in 
Parkinson’s disease [168,171,172]. The L-dopa in-
duced hyperhomocysteinemia may therefore con-
tribute to the loss of therapeutic effects of L-dopa 
in this disease. Based on these observations allosteric 
intramolecular mechanisms within the receptor can 
operate together with allosteric intermolecular 
mechanisms passing from one receptor to the other 
one via the interface resulting in negative or posi-
tive cooperativity and establishing the receptor-
receptor interactions.
10.  Role of receptor interacting 
proteins in the modulation of 
GPCR RMs
It should be underlined that GPCRs contain sequence 
motifs known to have a theoretical capacity to in-
teract with many other proteins. Such interactions 
will have an impact on the properties of the RMs 
formed through direct physical interactions be-
tween receptors like their compartmentalization. 
The integrated signaling of RMs are probably mod-
ulated by adaptor and scaffolding proteins [8,10,
140,173,174]. The long C-terminal tail and the long 
third intracellular loop have dominated these 
receptor-protein interactions which can be transi-
tory or more stable. They have a clearcut impact on 
downstream signaling, trafficking, subcellular locali-
zation and cytoskeletal associations [175,176] and 
several GPCRs interact with cytoskeletal anchoring 
polypeptides like D2 receptors with alpha-filamin 
[177] and A2A receptors with α-actinin [178].
Interactions between GPCRs and PDZ-domain 
containing proteins play a special role by defining 
the molecular composition of signaling complexes 
within microcompartments and the precise place-
ment of these complexes within the cell. Well-known 
proteins containing PDZ domains are PSD-95, Shank, 
and homers which function as multivalent scaffold 
proteins organizing receptor complexes and inter 
alia linking together NMDA, mGluR1α and mGluR5 
in the glutamate synapses forming a high molecular 
signaling complex [175]. This receptor complex is 
however not a heterodimer or a RM since direct phys-
ical interactions between the receptors do not ap-
pear to exist. This complex becomes stabilized in the 
synapse by becoming linked to the actin cytoskel-
eton. Taken together, the interaction between NMDA 
and group-I mGluRs is mainly an indirect one via the 
PSD-95, GKAP, Shank, homer protein complexes with 
homer proteins directly interacting with the group-1 
mGluRs. However, direct physical receptor interac-
tions between these receptors can still exist in cer-
tain plasma membrane microdomains resulting in 
the formation of a heterodimer or a RM. The actin 
cytoskeleton may also assist in stabilizing RMs with 
their direct physical receptor interactions [175].
It is of substantial interest that calmodulin, an 
intracellular acidic calcium binding protein and a 
major transducer of calcium information [179] can 
directly interact with the third intracellular loop 
of the D2 receptor [180]. Exogenous calmodulin 
binds to the Arg-rich epitope domain in the amino-
terminus in a calcium dependent manner to which 
also the C-terminal tail of the A2A receptor can 
bind and calcium induced activation of calmodulin 
inhibits Gi/o protein activation by the D2 receptor 
[180]. The functional relevance of this interaction 
has been further studied using a [35S]-GTPγS binding 
assay in A2A-D2 cotransfected CHO cells [170,181]. 
Calcium ions were found to highly significantly and 
substantially increase basal and dopamine induced 
G protein coupling in A2A-D2 cotransfected cells 
but not in cells transfected only with D2 receptors. 
It was speculated that calcium/calmodulin complex 
could release the D2 receptor-Gi/o complex from 
the stronger inhibition caused by the A2A receptor. 
Furthermore, Neve’s group has obtained indications 
that binding of endogenous calmodulin to the intra-
cellular loop 3 of the D2 receptor enhances the 
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inhibitory D2 receptor signaling to the adenylate 
cyclase [182]. It may therefore be that the results 
of Terasmaa et al [181] can be explained by the 
existence of two types of dimers in the A2A/D2 
cotransfected cells containing substantially higher 
densities of D2 receptor than of A2A receptors [183]. 
Thus, the existence of D2 homomers coupled to 
Gi/o and A2A-D2 heteromers with a reduced G pro-
tein coupling in the A2A/D2 cotransfected cells 
could help explain the additional increase in G pro-
tein activation found with combined treatment with 
DA and calcium ions through disruption by Ca2+/
calmodulin of the antagonistic A2A/D2 interaction 
at the Arg-rich epitopes. Recently it has been sug-
gested that the D2 receptor signaling in the A2A-D2 
RM may preferentially involve the activation of 
Gq/11-PLC pathway [184] which however, remains 
to be established.
Thanks to the pioneering study of Woods et al 
[185] an increased understanding has been obtained 
of how calmodulin interacts with the A2A and D2 
receptors. Mass spectrometric analysis revealed 
that electrostatic interactions involving the D2 re-
ceptor Arg rich epitope and several calmodulin 
acidic epitopes mediate the D2 receptor-calmodulin 
binding. The discovery was also made that calmod-
ulin can form multiple non-covalent complexes 
involving electrostatic interactions with an epitope 
located in the proximal segment of the C-terminal 
of the A2A receptors. The dynamics of the A2A-D2-
calmodulin interactions were also clarified by the 
ability of calmodulin to disrupt the electrostatic 
interaction between the D2 receptor epitope and 
the distal A2A receptor epitope in the C-terminal. 
Furthermore, calcium ions disrupted the binding 
of calmodulin to the D2 epitope but failed to do so 
at the A2A receptor epitope. These results give new 
models for A2A-D2-calmodulin interactions and il-
lustrate the impact of receptor interacting pro-
teins on the structure and function of RMs.
In 1990 we published the autoradiographic lo-
calization of mas proto-oncogene mRNA in rat brain 
using in situ hybridization [186]. The mas transcripts 
were linked to discrete nerve cell populations in the 
forebrain, especially in the limbic cortex, the olfac-
tory tubercle and the olfactory bulb. There was no 
clear link to the distribution of the Angiotensin II 
high affinity agonist binding sites mainly found in 
the brain stem, especially the autonomic nuclei 
[187] in spite of the demonstration that the mas 
oncogene enhances the angiotensin induced cal-
cium responses in cells with angiotensin receptors 
[188]. Also it was later on found based on studies 
in mas oncogene-deficient mice that there may exist 
direct interactions between mas and the angiotensin 
AT1 receptor in the amygdala with the heptahelical 
protein mas not being activated by angiotensin II 
[189]. Based on the mapping of mas mRNA levels 
discussed above it may be that the cortical limbic 
afferents to the amygdala contain mas protein in 
their nerve terminal networks on which AT1 recep-
tors also may be located giving a structural corre-
late to a colocation.
It is therefore of substantial interest that a het-
erodimerization between mas and AT1 has been 
recently demonstrated in FRET and BRET experi-
ments [190]. The heteromerization resulted in a 
reduction of AT1 signaling giving evidence that the 
role of this GPCR protein is to directly associate 
with the AT1 protein and via endogenous negative 
cooperativity bring down its AT1 signaling. There is 
no need to postulate that this heptahelical protein 
is an orphan receptor. In contrast, the receptor-
receptor interactions in AT1-bradykinin B1 receptor 
heteromers in nuc tractus solitarius [191] and in 
smooth muscle cells [42] lead to enhanced AT1 re-
ceptor signaling and vasopressor responses. Increased 
presence of the AT1-B2 receptor heteromer contrib-
utes to the development of angiotensin II hyper-
sensitivity in preeclampsia [192] and experimental 
hypertension [193].
Another interesting receptor interacting protein 
is adenosine deaminase (ADA) which metabolizes 
adenosine to inosine. This enzyme binds to cell 
surface A1 receptors as an ectoenzyme on the ex-
tracellular side [194] and is necessary for the high 
affinity agonist binding state of the A1 receptor 
[195]. An irreversible ADA inhibitor deoxycoforma-
cin fully counteracted the antagonistic A1/D1 re-
ceptor interaction in the A1-D1 RM. This action was 
not due to blockade of enzymatic activity but to 
altered ADA-A1 protein interactions leading to al-
tered allosteric mechanisms over the interface and 
loss of the A1 agonist high affinity state required for 
the A1/D1 receptor interaction [141]. A dysfunction 
of ADA may thus lead to exaggerated D1 signaling 
causing motor hyperactivity and EEG arousal.
11.  Drug development based on 
targeting the RMs
Due to the existence of classical and non-classical 
cooperative interactions in RMs involving both ex-
trinsic (induced by exogenous ligand) and intrinsic 
cooperativity (induced only via the receptor pro-
tein interfaces formed) taking place via allosteric 
mechanisms [8,10,14,76,141] novel receptor sub-
types can appear as discussed above. Thus, the 
pharmacology of the binding pockets of the differ-
ent receptors building up the RM can become 
markedly altered versus their pharmacology in the 
respective homomers. Through the operation of 
both exogenous and endogenous cooperativities, 
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an ample spectrum of pharmacological properties 
emerges in the RMs, which lead to the development 
of a novel neuropsychopharmacology.
This is the neuropsychopharmacology of the RMs, 
the hallmark being the use of combined agonist or 
antagonist treatment to optimally increase or re-
duce the signaling of one malfunctioning receptor 
in the RM. Thus, in addition to giving agonistic and 
antagonistic drugs acting on the malfunctioning 
receptor in the RM, other drugs are also given to 
increase or reduce the influence of surrounding re-
ceptors on the malfunctioning receptor in the RM. 
In this way also the doses of the combined drugs 
can be reduced leading to the appearance of fewer 
side effects but maintaining therapeutic effects 
[14]. The introduction of A2A antagonists combined 
with L-dopa in treatment of Parkinson’s disease 
gives proof of concept that novel treatments can 
be introduced based on receptor-receptor interac-
tions in RMs (Figure 2) [14,76,171]. Based on the 
putative existence of trimeric A2A/D2/CB1 RMs 
combined treatment with A2A and CB1 antagonists 
should also be considered in Parkinson’s disease 
(Figure 2).
The conformational changes in the receptors of 
the RM caused by the receptor-receptor interactions 
through extrinsic and intrinsic cooperativity can also 
produce novel interactions among the participating 
receptors also including ion channels and RTK re-
ceptors. Thus, a rich spectrum of functions may 
emerge due to the formation of RMs. It should also 
be considered that in the RM novel interactions 
may develop through extrinsic and intrinsic coop-
erativity with receptor interacting and membrane 
associated proteins like scaffolding and adapter 
proteins. Thus, through the formation or disruption 
of RM novel cognition-decoding systems may appear 
or disappear in the brain membranes at synaptic 
and extrasynaptic locations and be a major molec-
ular mechanism for learning and memory [14,76, 
196,197]. Interactions between synaptic and extra-
synaptic RMs with possible formation of new RMs 
may be a major mechanism for the integration of 
wiring and volume transmission [196,197].
The pharmacology of the RMs has also led to the 
introduction of bivalent ligands which can become 
useful in treatment of disease. On the basis of the 
existence of μ-δ opioid receptor heterodimers with 
δ ligands enhancing the efficacy of μ agonists, bi-
valent compounds have inter alia been developed 
built up of a μ agonist linked to a δ antagonist which 
show special analgesic properties [198]. The dis-
tance between the two components modulated the 
appearance of opioid tolerance and dependence 
giving indications that the bivalent ligands in fact 
targeted the μ-δ opioid receptor heterodimers.
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Figure 2 Scheme of receptor-receptor interactions in putative trimeric CB1/D2/A2A receptor mosaics in Parkinson’s 
disease (PD) mainly located on dorsal striatal glutamate terminals with (right) or without (left) combined treatment 
with low doses of L-dopa and A2A and CB1 receptor antagonists. Left panel: Reduced tone of DA in PD leads to reduced 
signaling of D2 receptors to AC (inhibited by D2) and to ion channels (not shown). Instead dominance of A2A and CB1 
receptor signaling will develop with increased inhibition of D2 receptor activity via antagonistic A2A/D2 and CB1/D2 
receptor-receptor interactions and increased AC activity over the A2A activated AC. As a result PKA is strongly acti-
vated mediating increases in P-MEK (MAPK kinase), P-CREB and increased phosphorylation of Thr34 in DARPP-32 turn-
ing it into a protein phosphatase type-1 inhibitor. This will cause inter alia increases in striatal excitability with 
increased release of glutamate leading to inhibition of motor function. Right panel: By means of combined therapy 
with A2A and/or CB1 receptor antagonists and removal of the antagonistic A2A/D2 and CB1/D2 receptor interactions 
it will be possible to use very low doses of L-dopa with reduced side-effects like L-dopa induced dyskinesias. A proper 
tone of D2 receptor activity can therefore be restored to ion channels (not shown) and to Gi/o regulated AC with nor-
malization of the activity of the A2A activated AC and reduction in the activity of PKA and thus in P-MEK, P-CREB and 
the activity of DARPP-32 and normalization of glutamate release.
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Specific ligands have also been developed for 
the κ-δ opioid heterodimer, one being a compound 
with κ agonist and δ antagonist properties and it 
should be noted that its specific analgesic proper-
ties are different from the actions of combined 
treatment with δ antagonists and κ agonists [199]. 
Again bivalent compounds have been synthesized 
that target the heterodimer in this case the κ-δ 
opioid heterodimer [200,201].
12.  RMs formed by GPCRs and ion 
channel receptors
The first one discovered was the one between GABAA 
and DA D5 receptors by Liu et al [202]. Coactivation 
of the two receptors is necessary for the forma-
tion of this RM with agonist-induced changes in the 
second intracellular loop of the γ subunit of the 
GABAA and in the C-terminal part of the D1 receptor 
being essential. One functional meaning of this RM 
appears to be the development of a mutually inhibi-
tory cross-talk between the two receptors. In view 
of this agonist dependency it may be that this RM is 
formed in a transient way within the plasma mem-
brane upon coactivation of the D5 and GABAA re-
ceptors in the surface membrane. GABAA receptor 
activation reduces D5/Gs coupling and D5 activa-
tion reduces the GABAA currents and thus synaptic 
strength at the GABA synapse [202]. The discovery 
of this GABAA and DA D5 RM gives new aspects on 
the role of these two receptors in schizophrenia 
[202,203].
This work was followed by the discovery of the 
constitutive D1/NMDA RM by Lee et al [144] where 
two regions exist in the C-terminal of the D1, one 
of them interacting with the NR1-1 and the other 
with the NR2A subunit of the NMDA receptor, re-
spectively (Figure 3A) [203]. The D1/NR2A interac-
tion reduced the NMDA currents upon D1 activation 
which may be caused at least in part by a reduced 
cell surface expression of the NMDA receptor [144]. 
There exist ER export signals in the C-terminal of 
the NR2 subunit that allows surface expression of 
assembled NMDA receptors. It was only in the pres-
ence of cotransfected NR2 subunits that the NR1-1 
subunit-D1 receptor complex could be translocated 
to the surface membrane and D1 activation can re-
duce this process [204]. However, as pointed out 
earlier D1-NMDA RMs may also be formed in the spine 
surface membrane by diffusing D1 being trapped 
by NMDA receptors [143].
Instead the D1/NR1-1a interactions were involved 
in the rescue of NMDA receptor induced excitotoxic-
ity by increasing the ability of the NR1-1a to form a 
complex with calmodulin and PI-3 kinase (Figure 3A) 
[144]. The two interacting regions of this interaction 
shows the presence of a phosphorylated serine 
and adjacent glutamates in the D1 receptor while 
NR1-1 contains three adjacent Arg residues which 
are all highly conserved [45]. Thus, similar elec-
trostatic interactions exist as in the interface of 
the A2A/D2 RM [45,92]. These epitope-epitope in-
teractions may represent general mechanism un-
derlying receptor-receptor interactions as proposed 
by Woods and colleagues, where phosphorylation and 
dephosphorylation processes can play an important 
role since phosphate stabilizes these electrostatic 
interactions [93].
Finally a constitutive D2-NMDA RM has been 
demonstrated [205] taking place between the 
N-terminal part of the third intracellular loop of 
the D2 and C-terminal of the NR2B subunit located 
in microdomains of postsynaptic densities of gluta-
mate synapses (Figure 3B). However, it was enhanced 
by D2 activation through cocaine treatment. This 
receptor-receptor interaction reduces the binding 
of Ca/calmodulin dependent protein kinase II to 
NR2B with diminished NR2B phosphorylation and re-
duction of NMDA signaling [205]. This RM may have 
a substantial role in Parkinson’s disease, schizophre-
nia and cocaine addiction.
Thus, there exist highly specific RMs between 
GPCRs and key ion channel receptors that will fine-
tune the excitability and firing of neural circuits in 
the brain involving modulation of phosphorylation 
and trafficking of the ion channel receptors to the 
surface membrane.
13.  Putative RMs formed by GPCRs and 
tyrosine receptor kinases (RTKs): 
one possible mechanism for 
transactivation of RTKs
Receptor tyrosine kinases are a family of membrane-
spanning receptors in mammals that mediate the 
TM signaling from ligands that include the majority 
of growth factor receptors, such as platelet-derived 
growth factor (PDGF), epidermal growth factor 
(EGF), neurotrophins (e.g., BDNF) and FGFs. In each 
case, dimerization and tyrosine phosphorylation of 
RTKs occur, and this phosphorylation serves as 
docking sites of adaptor proteins that lead to the 
activation of intracellular signaling pathways such 
as Ras-mitogen activated protein kinase (MAPK) 
cascade [206−208].
There is a new awareness that G protein-
coupled receptor (GPCR) possesses the capacity for 
transactivation of RTK via GPCR induced release of 
neurotrophic factors [207] and via Gbetagamma 
subunits mediated Src-dependent phosphorylation 
[208] leading to increases in mitogen-activated pro-
tein kinase activity. This rise is rapid and transient 
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and results in kinase translocation to the nucleus 
and transcriptional activation. It is of substantial 
interest that also beta-arrestins can bind to the 
GPCRs and transduce receptor signals causing a 
slow and sustained rise of MAPK activity mainly re-
stricted to the cytoplasm [209]. Over the past dec-
ade many examples of transactivation of mitogenic 
growth factor receptors in response to GPCR sign-
aling have been reported indicating that there are 
alternative modes of activating receptor tyrosine 
kinases in the absence of neurotrophic factor binding 
at the cell surface [207,210−215].
It has also been postulated that GPCRs and RTK 
can directly interact enabling allosteric receptor-
receptor interactions within a GPCR-RTK hetero-
dimer/RM like 5-HT1A-RTK fibroblast growth factor 
receptor 1 (FGFR1) [197]. Thus, direct GPCR-TRK 
receptor-receptor interactions in receptor het-
erodimer/RMs may develop in the cell surface 
membrane of substantial importance for neuronal 
trophism. It is therefore exciting to notice that 
Grengard and colleagues [216] in 2008 have dis-
covered a direct physical interaction between the 
A2A receptor and FGFR1 and coactivation but not 
individual activation of these two types of recep-
tors results in a marked activation of the MAPK/
ERK pathway. This event is associated with differ-
entiation, increased neurite extension, appearance 
of spines and striatal plasticity. It may play a cru-
cial role in the induction of enduring change in the 
CNS trophism via VT signals operating through com-
bined GPCR and RTK activation. The evidence [216] 
Figure 3 Scheme of the molecular mechanism for the receptor-receptor interactions in the D1/NMDA (A) and D2/
NMDA (B) receptor mosaics. (A) One epitope of the C-terminal region of D1 can directly interact with the C-terminal 
of the NR2A and reduce its plasma membrane expression resulting in reduction of NMDA currents and in reduced 
excitability; another epitope of the C-terminal region of D1 can directly interact with the NR1-1a increasing the abil-
ity of the NR1-1 to form a complex with calmodulin and PI-3 kinase resulting in increased activity of the PI-3 kinase 
and increased cell survival (see text for reference). (B) The N terminal part of the third intracellular loop of D2 
directly interacts with C terminal part of the NR2B subunit of synaptic NMDA receptors. This interaction is increased 
by D2 activation and reduces the binding of the calcium/calmodulin dependent protein kinase II to the NR2B which 
results in reduced phophorylation of the NR2B subunit, reduction of NMDA currents and thus reduced excitability (see 
text for reference).
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suggests that FGF may act as a co-transmitter through 
A2A receptors to modulate neuronal plasticity.
The hypothesis has been introduced that the 
neurotrophic system FGF-2/FGFR1 may be a good 
candidate to mediate antidepressant induced im-
provement in 5-HT neuronal communication and 
neurotrophism with regeneration of connections lost 
during depression and recovery from depression 
[197]. It also states that FGFR1 transactivation 
mediates the antidepressant effects of 5-HT uptake 
blockers and that the molecular mechanism involves 
a receptor-receptor interaction between certain 
serotonin receptor subtypes like 5-HT1A and FGFR1 
forming a RM [197].
14.  Nomenclature and criteria for the 
existence of heteromers
Pin et al [107] in the IUPHAR report have proposed 
to name the GPCR heterodimer with the names of 
the two receptors separated by a hyphen in alpha-
betical and numerical order e.g. D1-D2 receptor 
“for the D1-D2 heteromer”. In spite of the attrac-
tive simplicity we would agree with Ferre, Franco 
et al [217] to add “heteromer” after the word 
“receptor”. This would be an improvement in view 
of the lack of knowledge on receptor stoichiome-
try. However, we would prefer to use the term “re-
ceptor mosaic” which we introduced already 1982 
[5] when more that two receptors are involved in-
stead of “receptor heteromer”. The term “mosaic” 
implies the importance not only of stoichiometry 
but also of topology of the types of receptors pre-
sent. Mosaic also gives a fine word for the structure 
of the molecular fingerprint from which the intra-
membrane receptor-receptor interactions in the 
receptor assembly arise via allosteric interactions. 
The RM can be built up of homomers or of heterom-
ers and also be a mixture of homomers and heter-
omers. Finally we would recommend to use the word 
receptor and not subunit for the participating re-
ceptors in the RM in order to distinguish them from 
the subunits of the ion channel receptors which 
are not functional on their own.
We fully agree with the valuable criteria devel-
oped in the IUPHAR report for identification of re-
ceptor heteromers and appreciate their comment 
that as new criteria emerge they will become in-
corporated in the NC-IUPHAR recommendations.
In summary, the field of RM with their receptor-
receptor interactions continues to expand and rep-
resents a new principle in molecular medicine8 
that continues to lead to new strategies in treat-
ment of mental and neurogical diseases as well as 
of diseases in the immune, cardiovascular and endo-
crine systems. A2A antagonists have already been 
introduced in Parkinson’s disease based on com-
bined treatment with low doses of levodopa ad D2 
agonists offered by the existence of antagonistic 
A2A/D2 interactions in A2A-D2 RMs [171].
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